Lucy Scientific Discovery Appoints Former B.C. Solicitor General Kash Heed as a Special Advisor
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or…
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or…
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) — Lucy Scientific Discovery Inc. (“Lucy” or…
LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) — (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”)…
LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) — (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”)…
DURHAM, N.C., March 29, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the…
DURHAM, N.C., March 29, 2023 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the…
The BIIB080 Phase 1b clinical study is the first to show a reduction of this…
The BIIB080 Phase 1b clinical study is the first to show a reduction of this…
WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company…
WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company…
PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies….
PMN310 demonstrated greater selectivity for target toxic oligomers over monomers compared to other amyloid-beta-directed antibodies….
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular…
SUNNYVALE, Calif., March 29, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular…
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases SAN FRANCISCO, March…
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory Diseases SAN FRANCISCO, March…
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to…
– Phase 2b clinical trial for AB-2004 in autism irritability ongoing and enrollment anticipated to…
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease…
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease…